HC Wainwright Lowers Allogene Therapeutics (NASDAQ:ALLO) Price Target to $23.00
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price objective lowered by HC Wainwright from $29.00 to $23.00 in a research note published on Tuesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Allogene Therapeutics’ Q1 2023 earnings at ($0.61) EPS, Q2 2023 […]